Harmless virus associated with longer life for some HIV-positive men

March 03, 2004

Scientists have shown that an apparently harmless virus is associated with longer life for HIV-positive men, but only when it infects them for many years.

Men infected with both HIV and GB virus type C (GBV-C), previously known as hepatitis G, for at least five years were three times less likely to die than HIV-positive men who did not have GBV-C. The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, appears in the March 4 issue of The New England Journal of Medicine.

"We found strong evidence that HIV-positive men who have persistent GBV-C infection survive longer than those who do not have GBV-C. The survival advantage is large and depends on how long the GBV-C infection persists," says senior investigator Jack Stapleton, M.D., of the University of Iowa and Iowa City Veterans Affairs Medical Center. Carolyn Williams, Ph.D., epidemiology branch chief in NIAID's Division of AIDS, was the lead investigator on this study.

GBV-C, a virus that infects white blood cells, does not cause any known disease. It is transmitted through blood and blood products, and many people carry the virus, some for up to 40 years. Earlier studies have reported improved survival for HIV-positive persons co-infected with GBV-C, but the idea has been controversial. While some investigators found a survival advantage for HIV-positive men with GBV-C infection, others did not. This new study is the first to take into account the duration of GBV-C infection.

Dr. Williams and NIAID established a collaboration between the Multicenter AIDS Cohort Study (MACS) and Dr. Stapleton's laboratory in hopes of finding conclusive evidence on whether GBV-C infection prolonged the lives of HIV-positive men. The MACS (http://www.niaid.nih.gov/reposit/macs.htm), a long-term ongoing study of men who have sex with men, allows researchers to examine various factors that affect the progression of HIV infection and AIDS. Blood samples preserved by the MACS enabled Dr. Stapleton's group to determine whether there were differences in survival of HIV-positive men based on whether and for how long they had GBV-C infection.

Their results show that men who had GBV-C infection in two blood samples taken at least five years apart lived the longest. Eleven years after contracting HIV, 75 percent of the men who had GBV-C in both these blood samples were alive. Of the men who did not have GBV-C in either blood sample, only 39 percent survived for 11 years. The men who had GBV-C in their first blood sample but not in the second had the greatest risk of dying. Only 16 percent of them were still living after 11 years.

The researchers studied 271 MACS participants who became HIV-positive only after enrolling in MACS. The MACS provided Dr. Stapleton's team with blood samples for each man in the study group. Early blood samples for all 271 participants were drawn within 18 months of when the participant contracted HIV. Later blood samples--for various reasons, available for only 138 of the 271 participants--were drawn five to six years later. The researchers used blood samples collected before Jan. 1, 1996, to examine the interaction of the two viruses in this group of individuals before the widespread use of newer AIDS drugs in highly active antiretroviral therapy.

The researchers analyzed survival of the HIV-positive men based on whether they did or did not have GBV-C infection in their early blood sample. Using only the early blood sample data, the researchers found that men who had GBV-C did not survive any longer than those who did not. This finding is consistent with previous studies that did not find a survival advantage in early GBV-C infection for HIV-positive men co-infected with GBV-C.

Investigators then evaluated survival based on whether the men were still infected with GBV-C in their later blood sample. These MACS findings suggest that the survival advantage associated with GBV-C is evident only for HIV-positive men who have long-term infection with GBV-C, and that the previous studies did not find this advantage because they did not consider the duration of the GBV-C infection.

Why men with persistent GBV-C infection survive longer is not known, the researchers say. Dr. Stapleton's studies on cells grown in the laboratory suggest that GBV-C inhibits HIV from growing in human cells. However, the researchers also acknowledge that other factors related to the individual or to HIV might also be responsible for the survival advantage. Previous studies of GBV-C and HIV have shown that people infected with both viruses had slower decline in the number of key immune system cells compared to HIV-positive individuals who didn't have GBV-C infection. The MACS study confirms these findings as well. Dr. Stapleton's team and the MACS study group are continuing this work to help understand why and how GBV-C gives HIV-positive men a survival advantage.

Questions remain as to why some of the men cleared the GBV-C virus from their systems and why this was associated with an earlier death. Additional studies could answer these questions and offer new insights on how to control the progression of AIDS.

Researchers at Johns Hopkins University, Northwestern University, University of Pittsburgh, University of California, Los Angeles and Roche Diagnostics are co-authors on the new paper.

NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.
-end-
Reference: JT Stapleton et al. Persistent GB virus type C infection and survival in HIV-infected men. The New England Journal of Medicine 350(10):981-90 (2004).

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.